Rheumatology

Back to articles

Biosimilar TNF-α inhibitors are good alternative options to reference biologics

KEY POINT

Biosimilar versions of tumor necrosis factor–alpha (TNF-α) inhibitors may be viable substitutions for their biologic reference drugs, with data supporting similar pharmacokinetic parameters, efficacy, and safety outcomes, according to results of a systematic review published online in the Annals of Internal Medicine.

SOURCES

Chingcuanco F, et al. Bioequivalence of biosimilar tumor necrosis factor-α inhibitors compared with their reference biologics: A systematic review. Ann Intern Med. 2016;[Epub ahead of print].  

Zineh I, et al. The biosimilarity concept: Toward an integrated framework for evidence assessment. Ann Intern Med. 2016;[Epub ahead of print].